Corcept Therapeutics Incorporated
HealthcareNASDAQ:CORT · NASDAQ Capital Market
-$0.34 today
Vol 0.72M · Avg 1.41M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$769.1M of revenue converted into $47.9M of net income for the selected period. Gross margin is 98.3% and net margin is 5.2%, showing how much revenue survives after costs and taxes. EPS is $0.35, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $761.4M +12.8% | $675.0M +39.9% | $482.4M +20.0% | $401.9M +9.8% | $366.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $13.0M +19.3% | $10.9M +67.9% | $6.5M +20.4% | $5.4M +2.0% | $5.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $748.4M +12.7% | $664.2M +39.6% | $475.9M +20.0% | $396.5M +9.9% | $360.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 98.3% -0.1pp | 98.4% -0.3pp | 98.7% -0.0pp | 98.7% +0.1pp | 98.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $254.9M +3.2% | $246.9M +33.9% | $184.4M +40.7% | $131.0M +15.0% | $113.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $448.7M +60.1% | $280.3M +52.1% | $184.3M +20.6% | $152.8M +24.9% | $122.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $703.6M +33.5% | $527.2M +43.0% | $368.6M +29.9% | $283.8M +20.2% | $236.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.9M +41.5% | $1.3M +28.2% | $1.0M -17.2% | $1.3M -59.0% | $3.1M | $374.2M | $1.2B | $631.8M |
| EBITDA | $68.4M -58.0% | $162.8M +29.6% | $125.6M +6.9% | $117.5M -8.2% | $128.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 9.0% -15.1pp | 24.1% -1.9pp | 26.0% -3.2pp | 29.2% -5.7pp | 35.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | $44.8M -67.3% | $137.0M +27.7% | $107.3M -4.8% | $112.6M -9.5% | $124.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 5.9% -14.4pp | 20.3% -2.0pp | 22.2% -5.8pp | 28.0% -6.0pp | 34.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $24.5M +42.1% | $17.3M +385.7% | $3.6M +572.4% | $529.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $21.7M -11.7% | $24.5M +42.1% | $17.3M +385.7% | $3.6M +572.4% | $529.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $66.5M -58.8% | $161.5M +29.7% | $124.6M +7.2% | $116.2M -7.1% | $125.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 8.7% -15.2pp | 23.9% -1.9pp | 25.8% -3.1pp | 28.9% -5.2pp | 34.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$33.2M -263.6% | $20.3M +10.1% | $18.4M +24.7% | $14.8M +18.2% | $12.5M | $1.3B | -$1.6B | $745.2M |
| Net Income | $99.7M -28.7% | $139.7M +31.6% | $106.1M +4.7% | $101.4M -9.9% | $112.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | 13.1% -7.6pp | 20.7% -1.3pp | 22.0% -3.2pp | 25.2% -5.5pp | 30.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 -29.6% | $1 +32.4% | $1 +7.4% | $1 -2.1% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 -33.3% | $1 +30.9% | $1 +8.0% | $1 -2.2% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $103.9M +0.6% | $103.2M -0.3% | $103.6M -3.0% | $106.8M -7.7% | $115.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $120.0M +5.7% | $113.5M +1.6% | $111.7M -3.6% | $116.0M -7.9% | $126.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.48B
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$13.13B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Cytokinetics, Incorporated
NASDAQ:CYTK
$8.73B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.24B
Merus N.V.
MRUS
$6.83B
Abivax S.A.
NASDAQ:ABVX
$6.33B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.06B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.08B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CORT generate?
Corcept Therapeutics Incorporated (CORT) reported $761.41M of revenue in fiscal 2025.
Is CORT profitable?
Corcept Therapeutics Incorporated (CORT) reported $99.65M of net income, with a net margin of 13.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.